SMT202200067T1 - Agonisti fenilpirrolidinonici del recettore 2 dei formil peptidi - Google Patents

Agonisti fenilpirrolidinonici del recettore 2 dei formil peptidi

Info

Publication number
SMT202200067T1
SMT202200067T1 SM20220067T SMT202200067T SMT202200067T1 SM T202200067 T1 SMT202200067 T1 SM T202200067T1 SM 20220067 T SM20220067 T SM 20220067T SM T202200067 T SMT202200067 T SM T202200067T SM T202200067 T1 SMT202200067 T1 SM T202200067T1
Authority
SM
San Marino
Prior art keywords
phenylpyrrolidinone
receptor agonists
formyl peptide
formyl
peptide
Prior art date
Application number
SM20220067T
Other languages
English (en)
Italian (it)
Inventor
Pravin Sudhakar Shirude
Vishweshwaraiah Baligar
Balaji Seshadri
Amit Kumar Chattopadhyay
Nicholas R Wurtz
Ellen K Kick
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SMT202200067T1 publication Critical patent/SMT202200067T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/304—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
SM20220067T 2018-03-05 2019-03-04 Agonisti fenilpirrolidinonici del recettore 2 dei formil peptidi SMT202200067T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862638556P 2018-03-05 2018-03-05
EP19711769.0A EP3762380B1 (en) 2018-03-05 2019-03-04 Phenylpyrrolidinone formyl peptide 2 receptor agonists
PCT/US2019/020493 WO2019173182A1 (en) 2018-03-05 2019-03-04 Phenylpyrrolidinone formyl peptide 2 receptor agonists

Publications (1)

Publication Number Publication Date
SMT202200067T1 true SMT202200067T1 (it) 2022-03-21

Family

ID=65812419

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220067T SMT202200067T1 (it) 2018-03-05 2019-03-04 Agonisti fenilpirrolidinonici del recettore 2 dei formil peptidi

Country Status (30)

Country Link
US (3) US10676431B2 (enExample)
EP (2) EP3762380B1 (enExample)
JP (1) JP7155276B2 (enExample)
KR (1) KR102803660B1 (enExample)
CN (1) CN111868052B (enExample)
AR (1) AR114429A1 (enExample)
AU (1) AU2019232704B2 (enExample)
BR (1) BR112020017744A2 (enExample)
CA (1) CA3092927A1 (enExample)
CL (1) CL2020002224A1 (enExample)
CY (1) CY1124985T1 (enExample)
DK (1) DK3762380T3 (enExample)
EA (1) EA202092094A1 (enExample)
ES (1) ES2904483T3 (enExample)
HR (1) HRP20220118T1 (enExample)
HU (1) HUE058044T2 (enExample)
IL (1) IL277044B2 (enExample)
LT (1) LT3762380T (enExample)
MX (1) MX2020009000A (enExample)
MY (1) MY204384A (enExample)
PE (1) PE20210046A1 (enExample)
PL (1) PL3762380T3 (enExample)
PT (1) PT3762380T (enExample)
RS (1) RS62833B1 (enExample)
SG (1) SG11202008504SA (enExample)
SI (1) SI3762380T1 (enExample)
SM (1) SMT202200067T1 (enExample)
TW (1) TWI804585B (enExample)
WO (1) WO2019173182A1 (enExample)
ZA (1) ZA202006115B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005756A (es) * 2015-11-24 2018-08-01 Squibb Bristol Myers Co Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
EP3634412A1 (en) 2017-06-09 2020-04-15 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EP3634956B1 (en) 2017-06-09 2021-04-07 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
US11180490B2 (en) 2017-06-09 2021-11-23 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615095B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
UA127897C2 (uk) 2018-03-05 2024-02-07 Аркус Байосайєнсіз, Інк. Інгібітори аргінази
EP3762380B1 (en) 2018-03-05 2021-12-15 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
JP7398455B2 (ja) 2018-11-26 2023-12-14 ブリストル－マイヤーズ スクイブ カンパニー ピラゾロンホルミルペプチド２受容体アゴニスト
ES2946673T3 (es) * 2019-06-18 2023-07-24 Bristol Myers Squibb Co Agonistas del FPR2 de óxido de biaril dialquil fosfina
KR20230038515A (ko) * 2020-07-09 2023-03-20 브리스톨-마이어스 스큅 컴퍼니 옥소피롤리딘 fpr2 효능제
WO2022035923A1 (en) * 2020-08-12 2022-02-17 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
US20240109897A1 (en) * 2021-01-21 2024-04-04 Beijing Tiantan Hospital Modulators of fpr1 and methods of using the same
JP7717816B2 (ja) * 2021-01-21 2025-08-04 バイオフロント セラピューティクス （ベイジン） カンパニー リミテッド Ｆｐｒ１のモジュレーター及びそれを使用する方法
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
IL313538A (en) 2021-12-15 2024-08-01 Adama Agan Ltd Useful compounds for the preparation of various agrochemicals and their markers
WO2023229034A1 (ja) 2022-05-27 2023-11-30 アサヒグループホールディングス株式会社 乳酸菌由来の外膜小胞を含有するｆｐｒ２作動剤
WO2024079252A1 (en) 2022-10-13 2024-04-18 Bayer Aktiengesellschaft Sos1 inhibitors
WO2024220487A1 (en) * 2023-04-18 2024-10-24 Bristol-Myers Squibb Company Carbocyclic phenylpyrrolidinone urea fpr2 agonists
CN120936594A (zh) * 2023-04-18 2025-11-11 百时美施贵宝公司 吡咯烷酮脲fpr2激动剂
WO2024220482A1 (en) * 2023-04-18 2024-10-24 Bristol-Myers Squibb Company Pyrrolidinone urea fpr2 agonists
WO2025202955A1 (en) 2024-03-28 2025-10-02 Pi Industries Ltd. Fused bicyclic compounds and their use as pest control agents

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202344A (en) 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
WO1995033719A1 (en) 1994-06-02 1995-12-14 Zeneca Limited Substituted pyrrolidone, thiazolidones or oxazolidones as herbicides
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
TWI354664B (en) * 2003-08-21 2011-12-21 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine rece
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP1692502A2 (en) 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
US7678913B2 (en) * 2004-12-07 2010-03-16 Portola Pharmaceuticals, Inc. Ureas as factor Xa inhibitors
WO2006063293A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. THIOUREAS AS FACTOR Xa INHIBITORS
US20070123508A1 (en) 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
EP1896461A2 (en) 2005-06-30 2008-03-12 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
KR101213007B1 (ko) 2007-12-18 2012-12-20 액테리온 파마슈티칼 리미티드 Ａｌｘ 작용제로서의 아미노트리아졸 유도체
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
USRE49686E1 (en) 2008-09-19 2023-10-10 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
KR20110117194A (ko) 2009-02-23 2011-10-26 에프. 호프만-라 로슈 아게 암 치료를 위한 신규한 오르토-아미노아미드
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
KR20120046159A (ko) 2009-06-12 2012-05-09 액테리온 파마슈티칼 리미티드 Ａｌｘ 수용체 아고니스트로서의 옥사졸 및 티아졸 유도체
WO2011163502A1 (en) 2010-06-24 2011-12-29 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
AU2011336973A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
US8846733B2 (en) 2010-12-07 2014-09-30 Actelion Pharmaceuticals Ltd. Oxazolyl-methylether derivatives as ALX receptor agonists
MX2013006420A (es) 2010-12-07 2013-07-29 Actelion Pharmaceuticals Ltd Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
AU2012214265A1 (en) 2011-02-11 2013-09-05 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
HRP20161786T1 (hr) 2011-05-13 2017-03-10 Array Biopharma, Inc. Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
MX376348B (es) 2011-10-26 2025-03-07 Allergan Inc Derivados de amida de aminoacidos sustituidos con n-urea como moduladores de receptor de tipo peptido receptor de formilo-1 (fprl-1).
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
KR20140145203A (ko) 2012-04-16 2014-12-22 알러간, 인코포레이티드 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
UA116455C2 (uk) 2012-11-13 2018-03-26 Еррей Біофарма Інк. Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
ES2708571T3 (es) 2013-07-16 2019-04-10 Allergan Inc Derivados de aminoácidos sustituidos con N-urea como moduladores del receptor de péptido formilado
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
SMT201800061T1 (it) 2013-11-28 2018-05-02 Kyorin Seiyaku Kk Derivati dell'urea o loro sali farmacologicamente accettabili utili come io agonisti del recettore del peptide formile di tipo i (fprl-1)
JP6524086B2 (ja) 2013-12-03 2019-06-05 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ ピロリジノン除草剤
CN109970614B (zh) 2014-05-15 2023-01-13 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
WO2016116900A1 (en) 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
CN107848962B (zh) 2015-05-27 2021-04-09 杏林制药株式会社 脲衍生物或其药理学上可接受的盐
ES2814126T3 (es) 2015-05-27 2021-03-26 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
MX2018005756A (es) 2015-11-24 2018-08-01 Squibb Bristol Myers Co Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
ES2901471T3 (es) 2015-12-10 2022-03-22 Bristol Myers Squibb Co Agonistas del receptor 2 de formilpéptido y del receptor 1 de formilpéptido de piperidinona
CN109563034A (zh) 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
KR102615095B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
EP3634956B1 (en) 2017-06-09 2021-04-07 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
US11180490B2 (en) 2017-06-09 2021-11-23 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EP3634412A1 (en) 2017-06-09 2020-04-15 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EP3762380B1 (en) 2018-03-05 2021-12-15 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Also Published As

Publication number Publication date
US20210371378A1 (en) 2021-12-02
LT3762380T (lt) 2022-02-25
EP3981767A1 (en) 2022-04-13
CA3092927A1 (en) 2019-09-12
US20200255375A1 (en) 2020-08-13
PL3762380T3 (pl) 2022-02-21
US11117861B2 (en) 2021-09-14
IL277044B2 (en) 2023-10-01
DK3762380T3 (da) 2022-01-17
IL277044B1 (en) 2023-06-01
ZA202006115B (en) 2022-06-29
KR102803660B1 (ko) 2025-05-02
EP3762380A1 (en) 2021-01-13
JP2021516240A (ja) 2021-07-01
SI3762380T1 (sl) 2022-09-30
JP7155276B2 (ja) 2022-10-18
BR112020017744A2 (pt) 2020-12-22
CN111868052B (zh) 2024-03-08
MX2020009000A (es) 2020-10-05
TWI804585B (zh) 2023-06-11
AR114429A1 (es) 2020-09-02
TW202000645A (zh) 2020-01-01
CY1124985T1 (el) 2023-01-05
HRP20220118T1 (hr) 2022-04-15
CL2020002224A1 (es) 2020-11-20
RS62833B1 (sr) 2022-02-28
HUE058044T2 (hu) 2022-06-28
IL277044A (en) 2020-10-29
AU2019232704A1 (en) 2020-10-22
CN111868052A (zh) 2020-10-30
EP3762380B1 (en) 2021-12-15
SG11202008504SA (en) 2020-10-29
EA202092094A1 (ru) 2020-12-10
AU2019232704B2 (en) 2024-03-21
ES2904483T3 (es) 2022-04-05
PE20210046A1 (es) 2021-01-08
US10676431B2 (en) 2020-06-09
US11708327B2 (en) 2023-07-25
WO2019173182A1 (en) 2019-09-12
PT3762380T (pt) 2022-01-25
KR20200128709A (ko) 2020-11-16
US20190270704A1 (en) 2019-09-05
MY204384A (en) 2024-08-27

Similar Documents

Publication Publication Date Title
ZA202006115B (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
PT3989972T (pt) Agonistas do recetor de péptido 1 de tipo glucagom
IL279300A (en) 1-GLP agonist receptors and their use
IL279224B1 (en) 1-glp agonist receptors and their use
IL280290A (en) IL2 agonists
PT3807267T (pt) Agonistas do recetor da hormona da tiroide e usos dos mesmos
ZA202101537B (en) Anti-trem-2 agonist antibodies
IL259791B (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
IL273253A (en) Glucagon-like peptide-1 receptor agonists and their uses
ZA202005419B (en) C-terminal antibody variants
EP3549948A4 (en) AGONISTIC PEPTIDE FOR ADIPONECTIN RECEPTOR
GB201816637D0 (en) Selective somatostatin receptor agonists
GB201810052D0 (en) Polypeptide
GB201817943D0 (en) Galanin-2 receptor agonists
IL299680A (en) Pyrazolone formyl peptide 2 receptor agonists
HK40039646A (en) Synthetic rig-i-like receptor agonists
GB201816747D0 (en) Linear apelin receptor agonists
GB201806655D0 (en) Polypeptide
GB201803074D0 (en) Peptide